SIR-Spheres® Y-90 resin microspheres are now FDA-approved for unresectable HCC, marking a unique approval for both HCC and mCRC in the U.S. The DOORwaY90 study showed a 98.5% overall response rate and ...

Expanded indication makes SIR-Spheres ® the first and only radioembolization therapy in the U.S. approved to treat both unresectable hepatocellular carcinoma and metastatic colorectal cancer WOBURN, ...

Newly published European Society for Medical Oncology (ESMO) clinical guidelines for the treatment of metastatic colorectal cancer (mCRC) endorse radioembolisation, specifically with Yttrium-90 resin ...

Sirtex Medical US Holdings, Inc. (Sirtex), a leading manufacturer of targeted liver cancer therapies, announced that enrollment in the US RESiN Registry has reached a milestone of 1,650 patients and ...

Sirtex Medical Inc. announced its dose sales for SIR-Spheres Y-90 resin microspheres have increased by 21.2% in the U.S. for the second quarter of 2015 compared to the second quarter of 2014, ...

The results, which could impact the treatment of tens of thousands of liver cancer patients annually, were announced by the principal investigator of the SARAH study, Professor Valérie Vilgrain MD, ...

Approval was based on results from the DOORwaY90 trial, which demonstrated a 98.5% overall response rate and 100% local tumor control in patients treated with the SIR-Spheres Y-90 resin microspheres ...